Patients (p) with advanced melanoma receiving rescue surgery (RS), BRAF inhibitors (BRAFi), immunotherapy (IT) or chemotherapy (CT) in an off-protocol, routine clinical setting.

e20046 Background: The treatment of advanced melanoma has evolved over the last three years to include novel treatments in addition to CT. However, the real value of these different therapies has yet to be examined in off-protocol routine clinical practice. Methods: We have retrospectively analyzed p with advanced melanoma treated in a single institution in an off-protocol routine clinical setting with CT, IT, BRAFi, RS, or imatinib (IM). Clinical factors, type of treatment and mutation status were correlated with progression-free survival (PFS) and overall survival (OS). Results: 68 p were included in the analysis. Median age, 61.4 years; 60.3% males. Predominant tumor sites: extremities (30.9%) or trunk (27.9%). Stage: 8.2% IIIA, 21.3% IIIB, 18% IIIC. 32.4% of p had BRAF mutations, 2.9% had cKIT mutations, and 14.7% had NRAS mutations. 74.2% had primary surgery without lymphadenectomy, 20.6% adjuvant IFN, 16.2% adjuvant radiotherapy. Adjuvant treatment was CT in 44.4% (28 p), BRAFi in 28.6% (18 p), IM i...